X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
clear cell-type renal cell carcinoma (4681) 4681
science & technology (4092) 4092
life sciences & biomedicine (3349) 3349
humans (2295) 2295
tumors (1748) 1748
kidney cancer (1625) 1625
oncology (1608) 1608
cancer (1454) 1454
metastases (1382) 1382
metastasis (1363) 1363
male (1288) 1288
female (1217) 1217
kidneys (1185) 1185
patients (1154) 1154
gene expression (1074) 1074
proteins (1013) 1013
renal cell carcinoma (1010) 1010
apoptosis (974) 974
middle aged (956) 956
kidney neoplasms - pathology (904) 904
carcinoma, renal cell (877) 877
carcinoma, renal cell - pathology (850) 850
medical prognosis (846) 846
kidney transplantation (844) 844
medicine (770) 770
aged (768) 768
kinases (747) 747
science & technology - other topics (736) 736
multidisciplinary sciences (732) 732
prognosis (681) 681
animals (673) 673
adult (649) 649
science (642) 642
research article (641) 641
cell biology (629) 629
carcinoma, renal cell - genetics (610) 610
cell proliferation (583) 583
analysis (578) 578
biomarkers (568) 568
pathology (557) 557
kidney neoplasms - genetics (545) 545
cancer therapies (530) 530
immunohistochemistry (500) 500
research (493) 493
signal transduction (491) 491
epithelial cells (480) 480
studies (474) 474
surgery (471) 471
cell line, tumor (469) 469
medicine, research & experimental (457) 457
research & experimental medicine (457) 457
genetic aspects (452) 452
mutation (452) 452
survival (447) 447
cell survival (442) 442
nephrectomy (441) 441
kidney diseases (436) 436
medical research (420) 420
genomes (418) 418
care and treatment (409) 409
kidney neoplasms - metabolism (398) 398
carcinoma, renal cell - metabolism (391) 391
genes (388) 388
mice (383) 383
cell migration (380) 380
inflammation (378) 378
biochemistry & molecular biology (372) 372
vascular endothelial growth factor (365) 365
urology & nephrology (364) 364
cell growth (360) 360
renal function (356) 356
urologic and male genital diseases (356) 356
cell cycle (352) 352
development and progression (352) 352
health aspects (352) 352
urology (351) 351
rodents (350) 350
clinical trials (345) 345
biology (338) 338
immunotherapy (334) 334
medicine & public health (324) 324
gene expression regulation, neoplastic (321) 321
aged, 80 and over (319) 319
diagnosis (316) 316
risk factors (311) 311
angiogenesis (309) 309
carcinoma, renal cell - drug therapy (306) 306
breast cancer (295) 295
deoxyribonucleic acid--dna (294) 294
ribonucleic acid--rna (292) 292
chemotherapy (290) 290
cytokines (285) 285
mirna (283) 283
hypoxia (276) 276
kidney neoplasms - drug therapy (274) 274
mesenchyme (274) 274
syngeneic grafts (274) 274
melanoma (271) 271
stem cells (271) 271
metabolism (266) 266
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5175) 5175
Chinese (30) 30
German (28) 28
Japanese (20) 20
French (3) 3
Italian (3) 3
Norwegian (3) 3
Russian (3) 3
Spanish (3) 3
Polish (2) 2
Korean (1) 1
Latvian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 11/2015, Volume 373, Issue 19, pp. 1803 - 1813
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2015, Volume 373, Issue 19, pp. 1814 - 1823
Journal Article
by Linehan, W. Marston and Spellman, Paul T and Ricketts, Christopher J and Creighton, Chad J and Fei, Suzanne S and Davis, Caleb and Wheeler, David A and Murray, Bradley A and Schmidt, Laura and Vocke, Cathy D and Peto, Myron and Al Mamun, Abu Amar M and Shinbrot, Eve and Sethi, Anurag and Brooks, Samira and Rathmell, W. Kimryn and Brooks, Angela N and Hoadley, Katherine A and Robertson, A. Gordon and Brooks, Denise and Bowlby, Reanne and Sadeghi, Sara and Shen, Hui and Weisenberger, Daniel J and Bootwalla, Moiz and Baylin, Stephen B and Laird, Peter W and Cherniack, Andrew D and Saksena, Gordon and Haake, Scott and Li, Jun and Liang, Han and Lu, Yiling and Mills, Gordon B and Akbani, Rehan and Leiserson, Mark D.M and Raphael, Benjamin J and Anur, Pavana and Bottaro, Donald and Albiges, Laurence and Barnabas, Nandita and Choueiri, Toni K and Czerniak, Bogdan and Godwin, Andrew K and Hakimi, A. Ari and Ho, Thai H and Hsieh, James and Ittmann, Michael and Kim, William Y and Krishnan, Bhavani and Merino, Maria J and Shaw, Kenna R. Mills and Reuter, Victor E and Reznik, Ed and Shelley, Carl S and Shuch, Brian and Signoretti, Sabina and Srinivasan, Ramaprasad and Tamboli, Pheroze and Thomas, George and Tickoo, Satish and Burnett, Kenneth and Crain, Daniel and Gardner, Johanna and Lau, Kevin and Mallery, David and Morris, Scott and Paulauskis, Joseph D and Penny, Robert J and Shelton, Candace and Shelton, W. Troy and Sherman, Mark and Thompson, Eric and Yena, Peggy and Avedon, Melissa T and Bowen, Jay and Gastier-Foster, Julie M and Gerken, Mark and Leraas, Kristen M and Lichtenberg, Tara M and Ramirez, Nilsa C and Santos, Tracie and Wise, Lisa and Zmuda, Erik and Demchok, John A and Felau, Ina and Hutter, Carolyn M and Sheth, Margi and Sofia, Heidi J and Tarnuzzer, Roy and Wang, Zhining and Yang, Liming and Zenklusen, Jean C and Zhang, Jiashan and Ayala, Brenda and Baboud, Julien and Chudamani, Sudha and Liu, Jia and Lolla, Laxmi and Naresh, Rashi and ... and The Cancer Genome Atlas Research Network and Canc Genome Atlas Res Network and Cancer Genome Atlas Research Network
The New England journal of medicine, ISSN 1533-4406, 01/2016, Volume 374, Issue 2, pp. 135 - 145
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2019, Volume 380, Issue 12, pp. 1116 - 1127
Among patients with advanced renal-cell carcinoma, overall survival and progression-free survival were longer among patients who received pembrolizumab and axitinib than among those who received... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Axitinib - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Aged, 80 and over | Adult | Female | Axitinib - adverse effects | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Survival Rate | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Sunitinib - adverse effects | Administration, Intravenous | Sunitinib - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Intention to Treat Analysis | Aged | Kidney Neoplasms - drug therapy | Axitinib | Dosage and administration | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Risk groups | Metastasis | Cancer therapies | Evidence-based medicine | Metastases | Pembrolizumab | Kidney cancer | Antitumor activity | Death | Blood pressure | Vascular endothelial growth factor | Drug dosages | Clear cell-type renal cell carcinoma | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article